International Journal of Community Medicine and Public Health,
Journal Year:
2023,
Volume and Issue:
11(1), P. 424 - 428
Published: Dec. 19, 2023
In
years,
there
have
been
advancements
in
laboratory
methods
for
detecting
and
monitoring
cancer
at
its
earliest
stages.
These
breakthroughs
revolutionized
the
field
of
care
with
a
focus
on
treatment
strategies.
This
review
explores
range
laboratory-based
approaches,
including
biopsies,
advanced
imaging
technologies
like
PET,
MRI,
CT
scans,
genomic
profiling
techniques
such
as
next-generation
sequencing
novel
biomarkers,
innovative
assay
platforms,
use
artificial
intelligence-driven
analytics.
Liquid
biopsies
are
particularly
valuable
they
provide
real-time
insights
into
tumor
dynamics
responses
to
by
analyzing
circulating
cells
cell-free
DNA.
Advanced
modalities
offer
enhanced
sensitivity
resolution
detection
tumors.
Genomic
help
unravel
complexities
tumors
guide
therapies.
Novel
biomarkers
show
promise
types
aiding
screening
prognosis
determination
monitoring.
Innovative
platforms
allow
analysis
improve
diagnosis.
The
integration
intelligence
(AI)
machine
learning
has
instrumental
interpreting
clinical
molecular
data
alongside
traditional
techniques.
However,
despite
progress
made
far
challenges
related
standardization,
cost
effectiveness,
ethical
considerations
persist.
It
is
crucial
integrate
these
practice
fully
exploit
their
potential
enhancing
care.
Molecular Oncology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 11, 2024
As
cutting‐edge
technologies
applied
for
the
study
of
body
fluid
molecular
biomarkers
are
continuously
evolving,
clinical
applications
these
improve.
Diverse
forms
circulating
have
been
described,
including
cell‐free
DNA
(cfDNA),
tumor
cells
(CTCs),
and
microRNAs
(cfmiRs),
although
unresolved
issues
remain
in
their
applicability,
specificity,
sensitivity,
reproducibility.
Translational
studies
demonstrating
utility
importance
cfmiRs
multiple
cancers
significantly
increased.
This
review
aims
to
summarize
last
5
years
translational
cancer
research
field
potential
diagnosis,
prognosis,
monitoring
disease
recurrence
or
treatment
responses
with
a
focus
on
solid
tumors.
PubMed
was
utilized
literature
search,
following
rigorous
exclusion
criteria
based
types,
patient
sample
size,
applications.
A
total
136
different
tumors
were
identified
divided
organ
sites,
number
found,
methodology,
types
biofluids
analyzed.
comprehensive
emphasizes
summarizes
underserved
areas
where
more
validations
needed.
ESMO Open,
Journal Year:
2023,
Volume and Issue:
8(6), P. 102051 - 102051
Published: Nov. 10, 2023
In
the
setting
of
localized
colon
cancer
(CC),
circulating
tumor
DNA
(ctDNA)
monitoring
in
plasma
has
shown
potential
for
detecting
minimal
residual
disease
(MRD)
and
predicting
a
higher
risk
recurrence.
With
tumor-only
sequencing
approach,
however,
germline
variants
may
be
misidentified
as
somatic
variations,
precluding
possibility
tracking
up
to
11%
patients
due
lack
known
mutations.
this
study,
we
assess
value
adding
white
blood
cells
(WBCs)
tissue
enhance
accuracy
results.
ESMO Gastrointestinal Oncology,
Journal Year:
2024,
Volume and Issue:
4, P. 100068 - 100068
Published: June 1, 2024
•ctDNA
is
a
strong
predictor
of
recurrence
un
CRC
patients
after
curative
surgery.•ctDNA
promising
biomarker
to
select
with
resected
colon
cancer
for
adjuvant
chemotherapy.•ctDNA
analysis
methods
should
be
chosen
adequately
fit
the
goal
personalized
treatment
approach.
Circulating
tumor
DNA
(ctDNA)
has
been
studied
as
non-invasive
tool
disease
monitoring
in
different
types.
Despite
advances
colorectal
(CRC)
management,
it
remains
leading
cause
mortality
and
there
an
unmet
need
new
biomarkers
guide
therapeutic
approaches
improve
patient's
outcome
surgical
resection
primary
or
its
metastatic
sites.
This
review
summarizes
clinical
results
ongoing
studies
on
performances
ctDNA
prognostic
marker
recurrence,
both
non-metastatic
those
full
disease.
Immunotherapy,
Journal Year:
2024,
Volume and Issue:
16(5), P. 319 - 329
Published: Jan. 10, 2024
A
consensus
guideline,
iRECIST,
was
developed
by
the
Response
Evaluation
Criteria
in
Solid
Tumours
(RECIST)
working
group
for
use
of
modified
RECIST
version
1.1
cancer
immunotherapy
trials.
iRECIST
designed
to
separate
pseudoprogression
from
real
progression.
However,
this
is
not
only
ambiguous
situation.
In
clinical
trials,
stable
disease
may
reflect
three
tumor
responses,
including
disease,
progressive
and
responsive
disease.
The
prediction
a
"true
complete/partial
response"
also
important.
Much
data
has
accumulated
showing
that
ctDNA
can
guide
decisions
at
point;
thus,
integrating
into
criteria
help
distinguish
true
response
type
earlier
patients
treated
with
immunotherapy;
however,
prospectively
validation
studies
are
needed.
The Journal of Liquid Biopsy,
Journal Year:
2024,
Volume and Issue:
4, P. 100148 - 100148
Published: March 13, 2024
Colon
cancer
(CC)
is
one
of
the
most
frequent
cancers
worldwide
being
responsible
for
over
500
thousand
deaths
in
2022.
Its
financial
and
human
burden
expected
to
increase
next
decades
accompanying
growing
aging
global
population.
Much
this
could
be
alleviated
considering
that
lethality
CC
mostly
due
its
late
diagnosis
failure
individualized
management
patients.
Coordinated
government
actions
implementation
better
diagnostic
tools
capable
detecting
earlier
tracking
tumoral
evolution
are
mandatory
achieve
a
reduction
CC's
social
impact.
CtDNA-based
liquid
biopsy
(LB)
has
great
potential
contribute
patients'
screening
adhesion,
detection,
longitudinal
tumor
follow-up.
In
review,
we
will
discuss
latest
epidemiological
data
on
disease,
diagnostic,
subtypes,
genetics,
treatment
focusing
advantages
limitations
ctDNA-based
LB,
including
important
bottlenecks
solutions
necessary
clinical
translation.
The
ctDNA-directed
trials
also
examined.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(23), P. 3960 - 3960
Published: Nov. 26, 2024
mGEC
is
associated
with
poor
overall
survival
(OS)
of
approximately
4–10
months.
CtDNA
emerging
as
a
promising
prognostic
biomarker
high
potential
for
early
relapse
detection.
However,
until
now,
there
was
little
knowledge
on
serial
ctDNA
detection
and
its
impact
treatment
evaluation
prognosis
in
mGEC.
Methods:
(ddPCR)
carried
out
serially
37
matched
tissue
(NGS)
patients
prior
to
systemic
initiation
every
two
weeks
thereafter
restaging
(n
=
173
samples).
The
results
have
been
correlated
response
(restaging
CT),
(OS),
progression-free
(PFS).
Results:
pretherapeutic
rate
77.8%.
Response
assessment
correct
54.2%
(pretherapeutically
pos./neg.)
85.7%
(dynamics
at
week
4).
Moreover,
decline
(MAF
%)
below
57.1%
the
value
after
2
accompanied
by
sensitivity
specificity
90%
(AUC
0.73)
(response
CT
3
months)
evaluating
76.5%
correctly
only
weeks.
In
contrast
mere
positivity
(p
0.445),
dynamics
under
initial
significantly
OS
(4.1
(95%
Cl
2.1–6.1)
vs.
13.6
CI
10.4–16.6)
months,
p
<
0.001)
PFS
(3.2
(1.9–4.5)
9.5
5.5–13.5)
treatment.
Additionally,
change
detectability
from
positive
levels
negative
during
similar
who
were
always
regarded
ctDNA-negative
(9.5
(95%Cl
0.4–18.5)
9.6
1.3–17.9)).
absence
becoming
undetectable
worse
(4.7
months).
Conclusions:
additional
allowing
saving
unevaluated
time
mGEC,
could
allow
an
anticipated
benefit
future.
